These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 18729265)

  • 1. [Innovations with system disrupting potential? New drugs of high value].
    Pfannkuche MS; Glaeske G
    Pharm Unserer Zeit; 2008; 37(5):416-22. PubMed ID: 18729265
    [No Abstract]   [Full Text] [Related]  

  • 2. Which tyrosine kinase inhibitor, if any?
    Ruiz-Arguelles GJ
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):878-9. PubMed ID: 22252622
    [No Abstract]   [Full Text] [Related]  

  • 3. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
    Mross K
    Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270
    [No Abstract]   [Full Text] [Related]  

  • 4. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Playing Russian roulette with tyrosine kinase inhibitors.
    Szmulewitz RZ; Ratain MJ
    Clin Pharmacol Ther; 2013 Mar; 93(3):242-4. PubMed ID: 23340477
    [No Abstract]   [Full Text] [Related]  

  • 6. Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care.
    Keefe D; Anthony L
    Curr Opin Support Palliat Care; 2008 Mar; 2(1):19-21. PubMed ID: 18685389
    [No Abstract]   [Full Text] [Related]  

  • 7. [Protein tyrosine kinases as drug targets. An important group of intracellular regulators].
    Winckler T; Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2008; 37(5):370-80. PubMed ID: 18729262
    [No Abstract]   [Full Text] [Related]  

  • 8. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
    Eck MJ; Manley PW
    Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule inhibitors of tyrosine kinase: waiting for the good news in colorectal cancer as well.
    Sobrero A; Andretta V
    Onkologie; 2008 May; 31(5):224-5. PubMed ID: 18497509
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics.
    Kirkland LO; McInnes C
    Biochem Pharmacol; 2009 May; 77(10):1561-71. PubMed ID: 19167366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
    Brachmann S; Fritsch C; Maira SM; García-Echeverría C
    Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule tyrosine kinase inhibitor and depression.
    Quek R; Morgan JA; George S; Butrynski JE; Polson K; Meyer F; Demetri GD; Block SD
    J Clin Oncol; 2009 Jan; 27(2):312-3. PubMed ID: 19064960
    [No Abstract]   [Full Text] [Related]  

  • 13. [Sustainability and new anticancer drugs].
    Perrone F
    Recenti Prog Med; 2015 Jan; 106(1):11-3. PubMed ID: 25621773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.
    Carver BS
    J Urol; 2009 Sep; 182(3):833-4. PubMed ID: 19616224
    [No Abstract]   [Full Text] [Related]  

  • 15. [The role of therapeutic target tyrosine kinases and inhibitors and its current situation in bone and soft tissue tumor].
    Mukaihara K; Suehara Y
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):296-300. PubMed ID: 25966501
    [No Abstract]   [Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors in cancer therapy.
    Eckhardt S
    Anticancer Agents Med Chem; 2008 Jun; 8(5):461. PubMed ID: 18537528
    [No Abstract]   [Full Text] [Related]  

  • 17. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
    Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel tyrosine kinase inhibitors in the treatment of cancer.
    Ocana A; Serrano R; Calero R; Pandiella A
    Curr Drug Targets; 2009 Jun; 10(6):575-6. PubMed ID: 19519359
    [No Abstract]   [Full Text] [Related]  

  • 19. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Andersson M; Kamby C
    Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors.
    Katayama N; Orita M; Yamaguchi T; Hisamichi H; Kuromitsu S; Kurihara H; Sakashita H; Matsumoto Y; Fujita S; Niimi T
    Proteins; 2008 Dec; 73(4):795-801. PubMed ID: 18767165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.